Lepu Medical Technology (Beijing) Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Lepu (Beijing) Medical Equipment Co., Ltd. (referred to as "Lepu Medical", stock code 300003) was founded in 1999 and is one of the earliest enterprises in China to engage in the research and manufacturing of cardiovascular intervention medical devices. It is also awarded the National Heart Disease Intervention Diagnosis and Treatment Equipment and Equipment Engineering Technology Research Center by the Ministry of Science and Technology of the People's Republic of China. In 2009, it was one of the first listed companies on the Growth Enterprise Market, It is one of the few enterprises in the domestic high-end medical device field that can form strong competition with foreign products. For the past 20 years, the company has always focused on serving patients with cardiovascular diseases, adhering to research and development innovation, and continuously growing and breaking through in the fields of cardiovascular stents, cardiac pacemakers, cardiovascular drugs, and medical artificial intelligence. It has also undertaken multiple major national scientific research projects, including the National Development and Reform Commission's high-tech industrialization demonstration project, the National Ministry of Science and Technology's 863 Plan development project, and the Science and Technology Support Plan project. At present, the company has developed into a leading high-end medical product industry group for cardiovascular disease interventional diagnosis and treatment equipment in China, covering four major sectors: medical devices, medical products, medical services, and new medical formats. The company adheres to the gradient development principle of "pre research generation, registration generation, and production and sales generation". Based on coronary drug stents, it has entered the era of bioabsorbable medical devices and artificial AI intelligent medical devices. The company has heavyweight products such as the international second-generation bioabsorbable stent NeoVas and the new generation intravascular drug (paclitaxel) eluting balloon catheter Vesselin. The internationally leading artificial intelligence AI-ECG electrocardiogram analysis software system product has been approved by the US FDA, EU CE certification, and NMPA registration. It also has various technical features such as coronary drug stents, balloons, pacemakers, occluders, heart valves, and angiography machines IVD equipment and diagnostic reagents, surgical instruments, artificial intelligence electrocardiogram devices, and household intelligent medical devices. In 2020, the Hefei High tech Cardiovascular Hospital (Gaoxin Hospital) controlled by the company was approved by the Anhui Provincial Health Commission to establish the "Internet Hospital". In the future, the company will continue to improve the construction of a full lifecycle industrial platform covering the prevention, diagnosis, treatment, and rehabilitation of cardiovascular diseases, and is committed to creating a distinctive ecological platform of "cardiovascular health+anti-tumor", providing advanced products and high-quality services for more patients with cardiovascular and tumor diseases. |
| Headquarter | Beijing |
| Establish Date | 6/11/1999 |
| Listed Code | 300003.SZ |
| Listed Date | 10/30/2009 |
| Chairman | Pu Zhongjie. |
| CEO | Zhang Zhibin. |
| Website | www.lepumedical.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
